10-Year Follow-Up: Pembrolizumab Outshines Ipilimumab in Advanced Melanoma
Long-term study shows pembrolizumab's superior efficacy over ipilimumab for advanced melanoma patients.
Phase 2 trial combines HDAC inhibitor and PD-1 inhibitor in pancreatic cancer, showing durable responses.
Meta-analysis reveals DPYD gene variants significantly increase death risk in fluoropyrimidine chemotherapy.